Search

Your search keyword '"Mildvan AS"' showing total 158 results

Search Constraints

Start Over You searched for: Author "Mildvan AS" Remove constraint Author: "Mildvan AS" Topic medicine Remove constraint Topic: medicine
158 results on '"Mildvan AS"'

Search Results

1. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults

3. Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study

4. Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202

5. Description of an efficacious behavioral peer-driven intervention to reduce racial/ethnic disparities in AIDS clinical trials

6. Changes in HIV-1 Subtypes B and C Genital Tract RNA in Women and Men After Initiation of Antiretroviral Therapy

7. Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients

8. Unnecessary Antibiotic Use Among Patients with Blood Cultures Positive for Viridans Streptococci

9. Predictors of Screening for AIDS Clinical Trials Among African-Americans and Latino/Hispanics Enrolled in an Efficacious Peer-Driven Intervention: Uncovering Socio-Demographic, Health, and Substance Use-Related Factors That Promote or Impede Screening

10. The Effect of Peer-Driven Intervention on Rates of Screening for AIDS Clinical Trials Among African Americans and Hispanics

11. Measurement of Naive CD4 Cells Reliably Predicts Potential for Immune Reconstitution in HIV

12. Intranasal Transmission of Hepatitis C Virus: Virological and Clinical Evidence

13. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment

14. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

15. Behavioral intervention improves treatment outcomes among HIV-infected individuals who have delayed, declined, or discontinued antiretroviral therapy: a randomized controlled trial of a novel intervention

16. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

18. A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV‐Specific Immunizations, and Interleukin‐2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024)

19. Gender differences in attitudes toward AIDS clinical trials among urban HIV-infected individuals from racial and ethnic minority backgrounds

20. Evidence That Intermittent Structured Treatment Interruption, but Not Immunization with ALVAC‐HIV vCP1452, Promotes Host Control of HIV Replication: The Results of AIDS Clinical Trials Group 5068

21. HIV and aging

22. ACT2 peer-driven intervention increases enrollment into HIV/AIDS medical studies among African-Americans/Blacks and Hispanics: A cluster randomized controlled trial

23. HIV Incidence Among Injection Drug Users in New York City, 1990 to 2002: Use of Serologic Test Algorithm to Assess Expansion of HIV Prevention Services

24. Changes in Weight and Lean Body Mass during Highly Active Antiretroviral Therapy

25. Immunophenotypic Markers and Antiretroviral Therapy (IMART): T Cell Activation and Maturation Help Predict Treatment Response

26. ???Informed Altruism??? and ???Partner Restriction??? in the Reduction of HIV Infection in Injecting Drug Users Entering Detoxification Treatment in New York City, 1990???2001

27. Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial

28. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients

29. Immune Reconstitution Is Comparable in Antiretroviral‐Naive Subjects after 1 Year of Successful Therapy with a Nucleoside Reverse‐Transcriptase Inhibitor– or Protease Inhibitor–Containing Antiretroviral Regimen

30. Can Immune Markers Predict Subsequent Discordance between Immunologic and Virologic Responses to Antiretroviral Therapy? Adult AIDS Clinical Trials Group

31. Short Communication: Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factorα, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2

32. HIV-Infected Individuals Who Delay, Decline, or Discontinue Antiretroviral Therapy: Comparing Clinic- and Peer-Recruited Cohorts

33. Kikuchi-Fujimoto disease and acute appendicitis

34. Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials

35. Effect of Ritonavir/Saquinavir on Stereoselective Pharmacokinetics of Methadone: Results of AIDS Clinical Trials Group (ACTG) 401

36. Human Immunodeficiency Virus Type 1 RNA Level and CD4 Count as Prognostic Markers and Surrogate End Points: A Meta-Analysis

37. GDP-Mannose Mannosyl Hydrolase Catalyzes Nucleophilic Substitution at Carbon, Unlike All Other Nudix Hydrolases

38. Cystic Fibrosis Transmembrane Conductance Regulator: Solution Structures of Peptides Based on the Phe508 Region, the Most Common Site of Disease-Causing ΔF508 Mutation

39. Evaluation of an Intensive Intermittent‐Induction Regimen and Duration of Short‐Course Treatment for Human Immunodeficiency Virus–Related Pulmonary Tuberculosis

40. Improved Survival and Reduced Clinical Progression in HIV-Infected Patients with Advanced Disease Treated with Saquinavir plus Zalcitabine

41. An Approach to the Validation of Markers for Use in AIDS Clinical Trials

42. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria

43. [Untitled]

44. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms

45. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?

46. Nested case-control study of the emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae

47. Escherichia coli orf17 Codes for a Nucleoside Triphosphate Pyrophosphohydrolase Member of the MutT Family of Proteins

48. Amphotericin B Lipid Complex Compared with Amphotericin B in the Treatment of Cryptococcal Meningitis in Patients with AIDS

49. Mechanism of Inhibition of Vaccinia DNA Topoisomerase by Novobiocin and Coumermycin

50. Predictors and Outcome of Multidrug-Resistant Tuberculosis

Catalog

Books, media, physical & digital resources